This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and biggest market movers. Market Checkup gives a full examination of a shocking medical device takeover, a hot biotech that can't find an acquirer, a surprise announcement bringing a failed drug, and a big deal in gene sequencing.

In this video, health-care analyst David Williamson discusses Oncothyreon's surprise 20% pop today. Its lung cancer vaccine Stimuvax, now under the name tecemotide, is back from its phase 3 trial failure last year. Oncothyreon's partner, the German pharma Merck KGaA, saw enough in a subgroup to start a new phase 3 trial. Watch and find out why, despite the seemingly good news, investors should be cautious about these developments.

David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.